To conclude, oncological patients treated with combination therapy of anti-PD-1/PD-L1 and anti-CTLA-4 can develop a particular pattern of T1DM, with very rapid onset within a few weeks after starting ICI therapy, even with a pre-existing T2DM. The gene discussed is PDCD1; the disease is type 1 diabetes mellitus.